203 related articles for article (PubMed ID: 30128866)
1. A Panel of Genes Identified as Targets for 8q24.13-24.3 Gain Contributing to Unfavorable Overall Survival in Patients with Hepatocellular Carcinoma.
Zhao K; Zhao Y; Zhu JY; Dong H; Cong WM; Yu Y; Wang H; Zhu ZZ; Xu Q
Curr Med Sci; 2018 Aug; 38(4):590-596. PubMed ID: 30128866
[TBL] [Abstract][Full Text] [Related]
2. Multiple genes identified as targets for 20q13.12-13.33 gain contributing to unfavorable clinical outcomes in patients with hepatocellular carcinoma.
Wang D; Zhu ZZ; Jiang H; Zhu J; Cong WM; Wen BJ; He SQ; Liu SF
Hepatol Int; 2015 Jul; 9(3):438-46. PubMed ID: 26067772
[TBL] [Abstract][Full Text] [Related]
3. Copy Number Aberrations of Multiple Genes Identified as Prognostic Markers for Extrahepatic Metastasis-free Survival of Patients with Hepatocellular Carcinoma.
Zhu ZZ; Bao LL; Zhao K; Xu Q; Zhu JY; Zhu KX; Wen BJ; Ye YQ; Wan XX; Wang LL; He SQ; Cong WM
Curr Med Sci; 2019 Oct; 39(5):759-765. PubMed ID: 31612394
[TBL] [Abstract][Full Text] [Related]
4. Loss at 16q22.1 identified as a risk factor for intrahepatic recurrence in hepatocellular carcinoma and screening of differentially expressed genes.
Chen L; Zhu ZZ; Liu SF; Wan X; Wen BJ; Jiang H; Zhu J; Cong WM
Neoplasma; 2016; 63(1):114-20. PubMed ID: 26639241
[TBL] [Abstract][Full Text] [Related]
5. Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma.
Patil MA; Gütgemann I; Zhang J; Ho C; Cheung ST; Ginzinger D; Li R; Dykema KJ; So S; Fan ST; Kakar S; Furge KA; Büttner R; Chen X
Carcinogenesis; 2005 Dec; 26(12):2050-7. PubMed ID: 16000397
[TBL] [Abstract][Full Text] [Related]
6. Detection of Novel Genomic Markers for Predicting Prognosis in Hepatocellular Carcinoma Patients by Integrative Analysis of Copy Number Aberrations and Gene Expression Profiles: Results from a Long-Term Follow-Up.
Cho HJ; Kim SS; Wang HJ; Kim BW; Cho H; Jung J; Cho SS; Kim JK; Lee JH; Kim YB; Yang MJ; Yoo BM; Lee KJ; Cho SW; Cheong JY
DNA Cell Biol; 2016 Feb; 35(2):71-80. PubMed ID: 26624274
[TBL] [Abstract][Full Text] [Related]
7. PTK2 and EIF3S3 genes may be amplification targets at 8q23-q24 and are associated with large hepatocellular carcinomas.
Okamoto H; Yasui K; Zhao C; Arii S; Inazawa J
Hepatology; 2003 Nov; 38(5):1242-9. PubMed ID: 14578863
[TBL] [Abstract][Full Text] [Related]
8. ATAD2 as a Poor Prognostic Marker for Hepatocellular Carcinoma after Curative Resection.
Hwang HW; Ha SY; Bang H; Park CK
Cancer Res Treat; 2015 Oct; 47(4):853-61. PubMed ID: 25687855
[TBL] [Abstract][Full Text] [Related]
9. Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival.
Roessler S; Long EL; Budhu A; Chen Y; Zhao X; Ji J; Walker R; Jia HL; Ye QH; Qin LX; Tang ZY; He P; Hunter KW; Thorgeirsson SS; Meltzer PS; Wang XW
Gastroenterology; 2012 Apr; 142(4):957-966.e12. PubMed ID: 22202459
[TBL] [Abstract][Full Text] [Related]
10. [Copy number aberrations of genes related to extrohepatic metastasis-free survival after operation for hepatocellular carcinoma].
Bao LL; Zhu ZZ; Wen BJ; Wan XX; Ye YQ; Chen L; He SQ; Cong WM
Zhonghua Gan Zang Bing Za Zhi; 2017 May; 25(5):349-353. PubMed ID: 28763841
[No Abstract] [Full Text] [Related]
11. Transcriptional analysis of the expression, prognostic value and immune infiltration activities of the COMMD protein family in hepatocellular carcinoma.
Wang X; He S; Zheng X; Huang S; Chen H; Chen H; Luo W; Guo Z; He X; Zhao Q
BMC Cancer; 2021 Sep; 21(1):1001. PubMed ID: 34493238
[TBL] [Abstract][Full Text] [Related]
12. Prediction of early-stage hepatocellular carcinoma using OncoScan chromosomal copy number aberration data.
Yu MC; Lee CW; Lee YS; Lian JH; Tsai CL; Liu YP; Wu CH; Tsai CN
World J Gastroenterol; 2017 Nov; 23(44):7818-7829. PubMed ID: 29209123
[TBL] [Abstract][Full Text] [Related]
13. [Association of chromosome 17q copy number variation with overall survival of patients with hepatocellular carcinoma and screening of potential target genes].
Zhang J; Wen B; Cong W; Chen L; Jiang J; Pan W; He J; Zhu Z
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2015 Oct; 32(5):615-9. PubMed ID: 26418977
[TBL] [Abstract][Full Text] [Related]
14. A copy number gain of the 6p arm is linked with advanced hepatocellular carcinoma: an array-based comparative genomic hybridization study.
Chochi Y; Kawauchi S; Nakao M; Furuya T; Hashimoto K; Oga A; Oka M; Sasaki K
J Pathol; 2009 Apr; 217(5):677-84. PubMed ID: 19097070
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of ATAD2 as a Potential Target in Hepatocellular Carcinoma.
Ekin U; Yuzugullu H; Ozen C; Korhan P; Bagirsakci E; Yilmaz F; Yuzugullu OG; Uzuner H; Alotaibi H; Kirmizibayrak PB; Atabey N; Karakülah G; Ozturk M
J Gastrointest Cancer; 2021 Dec; 52(4):1356-1369. PubMed ID: 34738187
[TBL] [Abstract][Full Text] [Related]
16. Integrated Bioinformatics Analysis of the Clinical Value and Biological Function of ATAD2 in Hepatocellular Carcinoma.
Meng X; Wang L; Zhu B; Zhang J; Guo S; Li Q; Zhang T; Zheng Z; Wu G; Zhao Y
Biomed Res Int; 2020; 2020():8657468. PubMed ID: 32462022
[TBL] [Abstract][Full Text] [Related]
17. High expression of PARD3 predicts poor prognosis in hepatocellular carcinoma.
Li S; Huang J; Yang F; Zeng H; Tong Y; Li K
Sci Rep; 2021 May; 11(1):11078. PubMed ID: 34040099
[TBL] [Abstract][Full Text] [Related]
18. NDRG1 as a biomarker for metastasis, recurrence and of poor prognosis in hepatocellular carcinoma.
Cheng J; Xie HY; Xu X; Wu J; Wei X; Su R; Zhang W; Lv Z; Zheng S; Zhou L
Cancer Lett; 2011 Nov; 310(1):35-45. PubMed ID: 21763068
[TBL] [Abstract][Full Text] [Related]
19. The abnormalities of chromosome 8 in two hepatocellular carcinoma cell clones with the same genetic background and different metastatic potential.
Yang J; Qin LX; Ye SL; Liu YK; Li Y; Gao DM; Chen J; Tang ZY
J Cancer Res Clin Oncol; 2003 May; 129(5):303-8. PubMed ID: 12750998
[TBL] [Abstract][Full Text] [Related]
20. CDCA5 overexpression is an Indicator of poor prognosis in patients with hepatocellular carcinoma (HCC).
Tian Y; Wu J; Chagas C; Du Y; Lyu H; He Y; Qi S; Peng Y; Hu J
BMC Cancer; 2018 Nov; 18(1):1187. PubMed ID: 30497429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
